Observational studyBMC neurology2026
Serum GPX4, ALOX15, and FPN1 are associated with severity of carotid atherosclerosis: a cross-sectional observational study.
Observational study in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCarotid atherosclerosis (CAS) is a major cause of ischemic stroke. Ferroptosis-related proteins glutathione peroxidase 4 (GPX4), arachidonate 15-lipoxygenase (ALOX15), and ferroportin-1 (FPN1) may be involved in atherosclerotic processes, but their clinical relevance in CAS remains unclear.
objectiveTo examine the associations of serum GPX4, ALOX15, and FPN1 with CAS severity and evaluate their discriminatory performance for severe carotid stenosis.
methodsThis cross-sectional observational study included 280 CAS patients classified into non-severe (n = 207) and severe (n = 73) stenosis groups. Serum GPX4, ALOX15, and FPN1 were measured by ELISA. Group differences were analyzed, ROC analysis assessed discriminatory performance, and logistic regression identified factors associated with severe CAS.
resultsSevere CAS patients were older and had higher proportions of diabetes, multiple plaques, and prior stroke. They also showed higher TC, LDL-C, hs-CRP, and IL-6, lower HDL-C, lower serum GPX4 and FPN1, and higher ALOX15. The AUCs were 0.721 for GPX4, 0.698 for FPN1, and 0.869 for ALOX15. The biomarker model yielded an AUC of 0.914. The combined model including clinical variables and the three biomarkers yielded an AUC of 0.991 and outperformed the clinical model alone. In multivariable analysis, age, HDL-C, Z-ln(hs-CRP), Z-ln(IL-6), GPX4, and ALOX15 remained independently associated with severe CAS.
conclusionSerum GPX4, ALOX15, and FPN1 were associated with CAS severity and provided additional discriminatory information for severe carotid stenosis in this cohort. Further longitudinal validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.